|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for GRM7 |
 Gene summary |
| Basic gene Info. | Gene symbol | GRM7 |
| Gene name | glutamate receptor, metabotropic 7 | |
| Synonyms | GLUR7|GPRC1G|MGLU7|MGLUR7|PPP1R87 | |
| Cytomap | UCSC genome browser: 3p26.1-p25.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_000844.3, NM_181874.2,NM_181875.1, | |
| Description | metabotropic glutamate receptor 7protein phosphatase 1, regulatory subunit 87 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 604101 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000196277 | ||
| HPRD : 04979 | ||
| Vega : OTTHUMG00000125549 | ||
| Protein | UniProt: Q14831 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_GRM7 | |
| BioGPS: 2917 | ||
| Pathway | NCI Pathway Interaction Database: GRM7 | |
| KEGG: GRM7 | ||
| REACTOME: GRM7 | ||
| Pathway Commons: GRM7 | ||
| Context | iHOP: GRM7 | |
| ligand binding site mutation search in PubMed: GRM7 | ||
| UCL Cancer Institute: GRM7 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0007194 | negative regulation of adenylate cyclase activity | 9144652 | GO:0007196 | adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway | 9473604 | GO:0007268 | synaptic transmission | 9473604 | GO:0030818 | negative regulation of cAMP biosynthetic process | 9144652 | GO:0031279 | regulation of cyclase activity | 9473604 |
| Top |
| Ligand binding site mutations for GRM7 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | L186 | E185K | UCEC | 2 | L355 | E356K | BLCA | 1 | T182 | T182M | BRCA | 1 | Y367 | E366K | COAD | 1 | K407 | Q409K | HNSC | 1 | T182 | T182M | HNSC | 1 | F195 | R197H | HNSC | 1 | F195 | F194L | HNSC | 1 | D92 | P93S | HNSC | 1 | G444 | A443V | HNSC | 1 | P175 | Q176L | LUAD | 1 | D92 | P93H | LUAD | 1 | N470 | N468S | LUAD | 1 | Y230 | S229T | LUAD | 1 | D92 | D92Y | LUAD | 1 | G444 | G444A | LUAD | 1 | G217 | G217S | SKCM | 1 | L186 | E185K | SKCM | 1 | L355 | T354A | SKCM | 1 | Y230 | G228E | SKCM | 1 | H77 | H77Y | SKCM | 1 | F195 | R197C | SKCM | 1 | T182 | A183T | STAD | 1 | V151 | V153A | STAD | 1 | L355 | E356A | STAD | 1 | Y367 | E366K | STAD | 1 | N371 | F372V | STAD | 1 | R359 | R360I | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for GRM7 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | T182 | T182M | 0.27554484 | H77 | H77Y | 0.11429586 | V151 | V153A | -1.3998358 | N470 | N468S | -1.2311407 | L355 | T354A | -1.1702382 | R359 | R360I | -1.1542857 | Y367 | E366K | -1.1264712 | L355 | E356A | -1.088957 | F195 | R197H | -1.0277077 | L355 | E356K | -1.0182278 | Y230 | S229T | -0.98967138 | D92 | P93S | -0.96392524 | G217 | G217S | -0.93096682 | N371 | F372V | -0.9198322 | K407 | Q409K | -0.90587712 | D92 | P93H | -0.89454049 | L186 | E185K | -0.8136391 | F195 | R197C | -0.75753916 | G444 | G444A | -0.6955108 | T182 | A183T | -0.49520468 | Y230 | G228E | -0.45780707 | F195 | F194L | -0.44804439 | G444 | A443V | -0.26558794 | D92 | D92Y | -0.2409741 | P175 | Q176L | -0.15435714 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for GRM7 from PDB |
| PDB ID | PDB title | PDB structure | 3MQ4 | Metabotropic glutamate receptor mGluR7 complexed with LY341495 antagonist |  |
| Top |
| Differential gene expression and gene-gene network for GRM7 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for GRM7 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C1263846 | Attention Deficit Disorder with Hyperactivity | 5 | Biomarker, GeneticVariation |
| umls:C0236969 | Substance-Related Disorders | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for GRM7 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Nutraceutical | DB00142 | L-Glutamic Acid | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of GRM7 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | MG | MAGNESIUM(2+) | 3mq4 | A | D92 | CA | CALCIUM(2+) | 5c5c | A | D92 | UNX | UNKNOWN ATOM OR LIGAND | 5c5c | A | G217 | UNX | UNKNOWN ATOM OR LIGAND | 5c5c | A | H77 Y367 N371 | CA | CALCIUM(2+) | 5c5c | A | L186 F195 N470 | UNX | UNKNOWN ATOM OR LIGAND | 5c5c | A | L355 R359 | UNX | UNKNOWN ATOM OR LIGAND | 5c5c | A | T182 | Z99 | (1S,2S)-2-[(2S)-2-AMINO-1-HYDROXY-1-OXO-3-(9H-XANTHEN-9-YL)PROPAN-2-YL]CYCLOPROPANE-1-CARBOXYLIC ACID | 3mq4 | A | T182 Y230 K407 | UNX | UNKNOWN ATOM OR LIGAND | 5c5c | A | V151 P175 G444 |
| Top |
| Conservation information for LBS of GRM7 |
| Multiple alignments for Q14831 in multiple species |
| LBS | AA sequence | # species | Species | A156 | VGVIGASGSSV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | A180 | PQISYASTAPE | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D189 | PELSDDRRYDF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D92 | DQINSDPNLLP | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F195 | RRYDFFSRVVP | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G158 | VIGASGSSVSI | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G217 | IVKALGWNYVS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G444 | EMEQAGGKKLL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G445 | MEQAGGKKLLK | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | H77 | RENGIHRLEAM | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | I89 | YALDQINSDPN | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K407 | YEQEGKVQFVI | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L186 | STAPELSDDRR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L216 | DIVKALGWNYV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L355 | FTSRTLENNRR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L448 | AGGKKLLKYIR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L95 | NSDPNLLPNVT | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L96 | SDPNLLPNVTL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | N358 | RTLENNRRNVW | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | N371 | EYWEENFNCKL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | N470 | VMFNKNGDAPG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | N90 | ALDQINSDPNL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | P175 | RLFQIPQISYA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | P56 | LGGLFPVHAKG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R281 | DTPNSRAVVIF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R359 | TLENNRRNVWF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R453 | LLKYIRNVNFN | 2 | Homo sapiens, Mus musculus | R453 | LLKYIRHVNFN | 1 | Rattus norvegicus | R72 | CGDIKRENGIH | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R78 | ENGIHRLEAML | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | S157 | GVIGASGSSVS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | S159 | IGASGSSVSIM | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | S181 | QISYASTAPEL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | S187 | TAPELSDDRRY | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | T108 | ARILDTCSRDT | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | T182 | ISYASTAPELS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V151 | KPEKVVGVIGA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V161 | ASGSSVSIMVA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y192 | SDDRRYDFFSR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y230 | ASEGSYGEKGV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y367 | VWFAEYWEENF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |